BioPharma Resources

Drug Trial Radar · NCT07213778

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

May 17, 2027

Study completion Jul 16, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Symptomatic Venous Thromboembolism (VTE)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • Acetylsalicylic Acid (ASA)Drug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of the composite endpoint of symptomatic VTE and all-cause deathTime frame: Through day 30 visit

Locations

57 sites in 5 countries. Site status is shown where the registry gives one.

  • Horizon Clinical Research

    La Mesa, California · Recruiting

  • Eisenhower Medical Center

    Rancho Mirage, California · Recruiting

  • CARI Clinical Trials

    Riverside, California · Recruiting

  • HCA HealthONE Centennial

    Englewood, Colorado · Recruiting

  • HCA HealthONE, HCA HealthONE Sky Ridge

    Lone Tree, Colorado · Recruiting

  • South Florida Joint Replacement Center

    Deerfield Beach, Florida · Recruiting

  • Delray Physician Care Center

    Delray Beach, Florida · Recruiting

  • Medical Research of Westchester - MPLUS Research Network

    Miami, Florida · Withdrawn

  • Larkin Community Hospital South Miami

    South Miami, Florida · Recruiting

  • Phoenix Clinical Research

    Tamarac, Florida · Recruiting

  • Endeavor Health

    Skokie, Illinois · Recruiting

  • The Orthopaedic Research Foundation, Inc.

    Indianapolis, Indiana · Recruiting

  • NextStage Clinical Research, St. Francis Medical Park

    Wichita, Kansas · Recruiting

  • Velocity Clinical Research, Annapolis

    Annapolis, Maryland · Recruiting

  • Mercy Medical Center

    Baltimore, Maryland · Recruiting

  • Sinai Hospital of Baltimore, Inc.

    Baltimore, Maryland · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Holy Name Medical Center

    Teaneck, New Jersey · Recruiting

  • NYU Langone

    New York, New York · Recruiting

  • Northwell Orthopaedic Institute

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • UBMD Orthopaedics and Sports Medicine

    Williamsville, New York · Recruiting

  • Atrium Health Musculoskeletal Institute and Sports Medicine

    Charlotte, North Carolina · Recruiting

  • Duke University Health System (Duke Health), Duke University Hospital

    Durham, North Carolina · Recruiting

  • Eximia Equihealth Research-Raleigh. LLC

    Raleigh, North Carolina · Recruiting

  • The Vein and Vascular Center at Raleigh Radiology

    Raleigh, North Carolina · Recruiting

  • Coastal Vascular Institute, PA

    Wilmington, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Ohio Clinical Trials

    Columbus, Ohio · Recruiting

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Keystone Clinical Studies LLC, dba Flourish Research

    Plymouth Meeting, Pennsylvania · Recruiting

  • HD Research - Memorial Hermann Village

    Houston, Texas · Completed

  • NextStage Clinical Research, All American Orthopedics and Sports Medicine

    Houston, Texas · Recruiting

  • Futuro Clinical Trials

    McAllen, Texas · Recruiting

  • Flourish Research - San Antonio (Formerly Clinical Trials of Texas)

    San Antonio, Texas · Recruiting

  • Endeavor Clinical Trials

    San Antonio, Texas · Withdrawn

  • DRx Clinical Research, LLC

    St. George, Utah · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.